

Special Issue

Human Papillomavirus Vaccine against Cervical Cancer and Beyond: Opportunities, Challenges and New Perspectives

Message from the Guest Editors

We are soliciting articles for a Special Issue of MDPI *Vaccines*, which will be entitled ‘Human Papillomavirus Vaccine against Cervical Cancer and Beyond: Opportunities, Challenges and New Perspectives’. It is now well known that Human Papilloma Virus (HPV) infection can lead to the development of genital warts, as well as cervical, anogenital, and oropharyngeal cancer. The World Health Organization (WHO) has recognized the importance of HPV-related diseases as a global public health issue, promoting HPV vaccination all over the world. Therefore, since 2006, many countries have implemented publicly funded HPV immunization programs, first targeting female adolescents and then progressively expanding HPV vaccination campaigns. Following the growing evidence of HPV-related diseases also in males, vaccines were then extended from female-only to gender-neutral populations. However, cervical cancer still remains a significant public health burden that requires further research work. Increasing awareness and understanding about the clinical value of vaccination, as well as extended investigations on emerging features of this HPV-related cancer, are needed.

Guest Editors

Dr. Rosa De Vincenzo

Dr. Alessandro Ghelardi

Dr. Ankica Lukic

Dr. Caterina Ricci

Deadline for manuscript submissions

closed (30 June 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/49256

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).